Feb 26, 2023 / 10:00PM GMT
Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria
Feb 26, 2023 / 10:00PM GMT
=====================
Corporate Participants
=====================
* Anthony S. Marucci
Celldex Therapeutics, Inc. - Founder, President, CEO & Director
* Diane C. Young
Celldex Therapeutics, Inc. - Senior VP & Chief Medical Officer
* Sarah Cavanaugh
Celldex Therapeutics, Inc. - SVP of Corporate Affairs & Administration
* Tibor Keler
Celldex Therapeutics, Inc. - Founder, Chief Scientific Officer & Executive VP
=====================
Conference Call Participants
=====================
* Evan Porter Taddeo
Guggenheim Securities, LLC, Research Division - Research Analyst
* Kristen Brianne Kluska
Cantor Fitzgerald & Co., Research Division - Analyst
* Samuel Evan Slutsky
LifeSci Capital, LLC, Research Division - Senior Research Analyst
* Thomas Jonathan Smith
SVB Securities LLC, Research Division - Senior MD of Immunology and Metabolism &
Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
